Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363982 · ClinicalTrials.gov registry record · NA
Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT05363982: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05363982 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363982, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this 8-week double-blind randomized placebo-controlled study is to assess the tolerability, safety, and efficacy of tPBM in adult patients with ASD.
Interventions
- DEVICE Transcranial Photobiomodulation (tPBM)
- DEVICE Placebo/ Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2024-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363982
The ClinicalTrials.gov registry entry for NCT05363982 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transcranial Photobiomodulation (tPBM) is the first listed.
NCT05363982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363982 about?
NCT05363982 is a clinical study titled "Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder". The purpose of this 8-week double-blind randomized placebo-controlled study is to assess the tolerability, safety, and efficacy of tPBM in adult patients with ASD.
What is the current status of trial NCT05363982?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2022-02-11. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT05363982?
The interventions under investigation include: Transcranial Photobiomodulation (tPBM) (DEVICE), Placebo/ Sham (DEVICE).
Who is sponsoring clinical trial NCT05363982?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.